Cargando…
Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197925/ https://www.ncbi.nlm.nih.gov/pubmed/37214470 http://dx.doi.org/10.3389/fphar.2023.1213053 |
| _version_ | 1785044643150299136 |
|---|---|
| author | Frontiers Production Office, |
| author_facet | Frontiers Production Office, |
| author_sort | Frontiers Production Office, |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10197925 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101979252023-05-20 Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis Frontiers Production Office, Front Pharmacol Pharmacology Frontiers Media S.A. 2023-05-05 /pmc/articles/PMC10197925/ /pubmed/37214470 http://dx.doi.org/10.3389/fphar.2023.1213053 Text en Copyright © 2023 Frontiers Production Office. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Pharmacology Frontiers Production Office, Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis |
| title | Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis |
| title_full | Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis |
| title_fullStr | Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis |
| title_full_unstemmed | Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis |
| title_short | Erratum: Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis |
| title_sort | erratum: comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network meta-analysis |
| topic | Pharmacology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197925/ https://www.ncbi.nlm.nih.gov/pubmed/37214470 http://dx.doi.org/10.3389/fphar.2023.1213053 |
| work_keys_str_mv | AT frontiersproductionoffice erratumcomparisonbetweendecitabineandazacitidineforpatientswithacutemyeloidleukemiaandhigherriskmyelodysplasticsyndromeasystematicreviewandnetworkmetaanalysis |